What is the price of Healios K.K. (4593)

The price of Healios K.K. (4593) is $1.89

What is the market cap of Healios K.K. (4593)

The market cap of Healios K.K. (4593) is $254.55M

Healios K.K. (4593) Dividends

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.

Year	Dividend (stock split adjusted)	Change
Not enough data for the provided dates.

Year

Dividend (stock split adjusted)

Change

Not enough data for the provided dates.

Year	Dividend	Change
Not enough data for the provided dates.

Year

Dividend

Change

Not enough data for the provided dates.

Company	Number of dividend payments	Country
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Moderna, Inc. MRNA.US	0.00%	US
CSL Limited CSL.AX	64.00%	AU
Lonza Group AG LONN.SW	0.00%	CH

Company

Number of dividend payments

Country